

Abstract

Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy- 5-(4-methylpiperazinylsulfonyl)phenyl] -1-methyl- 3-n-propyl-1, 6-dihydro-7H-pyrazolo[4, 3-d]pyrimidin -7-one, 4-phenylmethylamino -6-chloro-2- (1-imidazolyl) quinazoline, 4-phenylmethylamino -6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl- 6-(2-propoxy- 5-methanesulfonylamidophenyl)-1,5-dihdropyrazolo[3,4-d]pyrimidin -4-one or 1- cyclopentyl-3-ethyl-6-(3-ethoxy-4- pyridyl) -pyrazolo[3,4-d]pyrimidin -4-one.